Bioprocessing is a significant part of biopharmaceutical development and production processes and single-use bioprocessing systems, which are meant for one-time use, have recently found their unique position in the biopharmaceutical and biotherapeutics industry. Biomanufacturing facilities which once housed only stainless steel equipment are paving the way for a hybrid setup which also incorporates single-use technologies. New facilities manufacturing biologics, especially CRO’s/CMO’s and small biotechnology startups are increasingly opting for fully single-use plants. These systems have made the production of clinical trial drugs as well as commercially manufactured drugs cost-effective and flexible.
The highly consolidated single-use bioprocessing market is dominated by Thermo Fisher Scientific, Satorius AG, Merck KGaA, Pall Corporation, and GE Healthcare. Cumulatively, these companies accounted for a whopping 95.2% share in 2015, signaling the concentrated nature of the market by large and established players.
Get Free PDF Brochure for more Professional and Technical industry insights: http://bit.ly/2ck0vnq
Transparency Market Research estimates that the global single-use bioprocessing systems market will rise from a value of US$2.3 bn in 2015 to US$5.9 bn by 2024, expanding at a robust CAGR of 11.1% over the forecast period.
Robust Growth of Bioprocessing Bags Segment Attributed to Frequent and Recurring Purchases
Bioprocessing bags are projected to account for a 27.0% share by 2024, emerging as the leading product segment of the global single-use bioprocessing systems market. The robust growth of the bioprocessing bags segment can be attributed to frequent and recurring purchases for several upstream and downstream functions such as mixing, filtration, storage, transport, and media preparation and fermentation. The segment is also projected to expand at a strong CAGR of 14.8% from 2016 to 2024.
Accounting for the major share in the overall single-use bioprocessing systems market, the monoclonal antibody production segment is projected to continue its lead throughout the forecast period, exhibiting a growth rate higher than the other segments. By end use, the pharmaceutical segment is projected to dominate the market for single-use bioprocessing systems. However, the CRO and CMO segment is expected to gain much traction in the coming years, registering a high CAGR from 2016 to 2024.
Geographically, Europe was the leading market in 2015, accounting for a share of 29%. The region is likely to lose market share by 2024 but will continue its dominance throughout the forecast period. Registering a CAGR of 12.3%, Asia Pacific is projected to emerge as one of the fastest growing regions in the global single-use bioprocessing systems market.
Demand for Customized Single-use Products on the Rise
When it comes to single-use products, it is of utmost importance to customers that the use product in question be customized as per their requirements. “Single-use bags, bioreactors, and bioprocess containers are all amenable to customer-specific customization requests depending upon the application,” the TMR analyst states. This lends flexibility to the consumer, which is not always possible with capital equipment such as stainless steel bioprocess containers. This acts as a major growth driver.
View exclusive Global strategic Business report : http://www.transparencymarketresearch.com/single-use-bio-processing-systems-market.html
Other factors driving the single-use bioprocessing systems market include an overall reduction in cost, a reduction in clean-in-place (CIP) and steam-in-place (SIP) processes, minimized chances of cross-contamination, various technological advancements and innovations, and a growth in the production of monoclonal antibodies.
In contrast, various technical difficulties, environmental concerns regarding the use of disposables, and continued preference for stainless steel products over single-use technologies have been limiting the growth of the market.